设为首页  |   加入收藏

王雪融 药理学


发布时间: 2015-10-27 访问次数: 1865

王雪融,博士,教授,博士生导师

研究方向:肿瘤药理学和分子药理学

地址:南京市汉中路140号药理学系

邮编:210029

电话:025-86869406

E-mail:wangxr@njmu.edu.cn


   

王雪融,女,19742月出生,博士。南京医科大学基础医学院药理学系教授,博士生导师。2005年至2009年于美国爱默蕾大学做博士后和研究助理。目前主要研究抗肿瘤靶向治疗药物的作用机制和耐药机制,以及肿瘤转移的分子机制,力图找到药物作用的新靶点和提出新的治疗策略,增强药物的抗肿瘤作用。

研究兴趣和方向:肿瘤药理学和分子药理学。

主持课题:

1.国家自然科学基金“Glibenclamide通过靶向SUR1-p70S6K调控细胞代谢酶表达抑制非小细胞肺癌作用机制的研究(81473241)(2015-2018)”。

2.国家自然科学基金“IRS-1在头颈部鳞状上皮癌转移中作用和机制的研究(81172004)(2012-2015

3.国家自然科学基金“eIF4Eerlotinib耐药性中作用和机制的研究(81102458),(2012-2014

近期发表论文:

1.Shengjie Wu, Li Yang, Dandan Wu, Zhongyuan Gao, Ping Li, Wenbin Huang, Xuerong Wang. AEG-1 induces gastric cancer metastasis by upregulation of eIF4E expression. Journal of Cellular and Molecular Medicine. 2017 Jun 29. Doi: 10.1111/jcmm. 13258. [Epub ahead of print]

2.Dandan Wu, Jie Cheng, Geng Sun, Shengjie Wu, Min Li, Zhongyuan Gao, Sulan Zhai, Ping Li, Dongming Su, Xuerong Wang. p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma. Oncotarget. 2016 June 14; 7(24):36539-36550.

3.Xi Chen, Lingjun Zhu, Zhuo Ma, Geng Sun, Min Li, Sulan Zhai, Ping Li, Xuerong Wang. Oncogenic miR-9 is a target of erlotinib in NSCLCs. Scientific Reports. 2015 Nov; 5: 17031.

4.Meijuan Zou, Chen Hu, Qidong You, Aixia Zhang, Xuerong Wang (共同通讯作者), Qinglong Guo. Oroxylin A induces autophagy in human malignant glioma cells via the mTOR-STAT3-Notch signaling pathway. Molecular Carcinogenesis. 2015 Nov; 54(11): 1363-1375.

5.Yikun Li, Xuerong Wang(共同第一作者), Ping Yue, Hui Tao, Suresh S. Ramalingam, Taofeek K. Owonikoko, Xingming Deng, Ya Wang, Haian Fu, Fadlo R. Khuri, Shi-Yong Sun. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation. The journal of Biological Chemistry. 2013 May 10; 288(19): 13215-24.

6.Wenbin Huang, Li Yang, Song Liang, Dongxiao Liu, Xi Chen, Zhuo Ma, Sulan Zhai, Ping Li, Xuerong Wang. AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancer. Digestive Diseases and Sciences. 2013 Oct; 58(10): 2873-80.

7.Zhuo Ma, Lingjun Zhu, Xuan Luo, Sulan Zhai, Ping Li, Xuerong Wang. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells. Cancer Biology and Therapy. 2012 Sep; 13(11): 1009-1017. (IF = 2.636)

8.Xuerong Wang, Shi-Yong Sun. Enhancing mTOR-targeted cancer therapy. Expert Opinion on Therapeutic Targets. 2009 October 20; 13(10): 1193-1203.

9.Xuerong Wang, Natalyn Hawk, Ping Yue, John Kauh, Suresh S. Ramalingam, Haian Fu, Fadlo R. Khuri, and Shi-Yong Sun. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy. Cancer Biology and Therapy. 2008 December; 7(12) : 1952-1958.

10.Xuerong Wang, Ping Yue, Youngae Kim, Haian Fu, Fadlo R. Khuri, Shi-Yong Sun. Enhancing mTOR-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Research. 2008 September 15; 68 (18): 7409-7418.

11.Xuerong Wang, Ping Yue, Chi-Bun Chan, Keqiang Ye, Takeshi Ueda, Rie Watanabe-Fukunaga, Rikiro Fukunaga, Haian Fu, Fadlo R. Khuri, and Shi-Yong Sun. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3 kinase-dependent and Mnk-mediated eIF4E phosphorylation.Molecular and Cellular Biology. 2007 November; 27(21): 7405-7413.

  版权所有© 南京医科大学基础医学院
  Tel:025-86862876 Fax:025-86862912